Business
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update
Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell
About this update from Inmune Bio Inc.
[{"type":"text","content":"Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell Treatment Effective Against Solid Malignancies $66.7 Million in cash as of March 31, 2022 Company to Host Conference Call Today, May 5, at 4:30pm ET BOCA RATON, FL., May 05, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the quarter ended March 31, 2022 and provided a business update. Q1 2022 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™ and INB03): Dosed the first patient in the Phase II trial using XPro™ to treat patients with mild Alzheimer’s Disease (AD). The primary endpoint will examine cognition using the Early AD/MCI Alzheimer's Cognitive Composite (EMACC). Data is anticipated in the second half of 2023.Delivered multiple oral and poster presentations at AD/PD 2022 (International Conference on Alzheimer’s and Parkinson’s Disease).Presented breast cancer data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which suggested the use of INmune Bio’s DN-TNF candidate, INB03, may help reverse resistance to immunotherapy patients with HER2+ cancers. INKmune™ Platform Highlights: Planned expansion of INKmune program to include AML and new site in EU.2 of 3 patients with MDS/AML remain stable more than 6 months after the last treatment with INKmune.INKmune shows best-in-class therapeutic persistence measured by activated tumor killing NK cells (NKG2D+ NK cells) in the peripheral blood or bone marrow more than 100 days after INKmune™ treatment in the two patients with stable diseaseHighlighted the potential of INKmune primed NK cells to treat solid tumors by improving the ability of natural killer (NK) cells to survive hostile tumor microenvironments and by increased avidity, a necessary step for cancer cell killing, compared to NK cells primed with cytokines (IL-2, IL15). Upcoming Milestones: Initiate Xpro™ Phase 2 program for Mild Cognitive Impairment (MCI) in patients 1H 2022.Initiate XPro™ Phase 2 program for treatment resistant depression (TRD), funded in part by a $2.9 million NIH grant, by 2H 2022.Continued enrollment and opening o...